TGFB1 and prostate cancer: Benefiting from in-depth basic studies on TGF-β in relation to pancreatic, breast, and prostate cancers, drugs targeting TGF-β signaling combined with RT or chemotherapy have reached phase I-II clinical trials 12-15.